ECSP034826A - Método para fabricar una composición farmacéutica de dosis baja - Google Patents

Método para fabricar una composición farmacéutica de dosis baja

Info

Publication number
ECSP034826A
ECSP034826A EC2003004826A ECSP034826A ECSP034826A EC SP034826 A ECSP034826 A EC SP034826A EC 2003004826 A EC2003004826 A EC 2003004826A EC SP034826 A ECSP034826 A EC SP034826A EC SP034826 A ECSP034826 A EC SP034826A
Authority
EC
Ecuador
Prior art keywords
manufacturing
pharmaceutical composition
low dose
potency
drug
Prior art date
Application number
EC2003004826A
Other languages
English (en)
Inventor
Daniel Scott Gierer
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP034826A publication Critical patent/ECSP034826A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe un método para fabricar una composición farmacéutica que tiene una distribución y potencia del fármaco uniformes, el cual utiliza dióxido de silicio para reducir la pérdida de ingrediente activo durante el proceso de fabricación. El método es particularmente útil para la fabricación de composiciones para comprimidos de baja dosificación.
EC2003004826A 2001-05-01 2003-10-31 Método para fabricar una composición farmacéutica de dosis baja ECSP034826A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28784101P 2001-05-01 2001-05-01

Publications (1)

Publication Number Publication Date
ECSP034826A true ECSP034826A (es) 2004-02-26

Family

ID=23104578

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004826A ECSP034826A (es) 2001-05-01 2003-10-31 Método para fabricar una composición farmacéutica de dosis baja

Country Status (44)

Country Link
US (2) US7037530B2 (es)
EP (1) EP1383482B1 (es)
JP (1) JP2004531537A (es)
KR (1) KR100568380B1 (es)
CN (1) CN1240375C (es)
AP (1) AP2003002900A0 (es)
AR (1) AR033288A1 (es)
AT (1) ATE367152T1 (es)
AU (1) AU2002236166B2 (es)
BG (1) BG108297A (es)
BR (1) BR0209283A (es)
CA (1) CA2445519C (es)
CZ (1) CZ20032959A3 (es)
DE (1) DE60221238T2 (es)
DK (1) DK1383482T3 (es)
DO (1) DOP2002000389A (es)
EA (1) EA005949B1 (es)
EC (1) ECSP034826A (es)
EE (1) EE200300537A (es)
ES (1) ES2286226T3 (es)
GE (1) GEP20053654B (es)
GT (1) GT200200078A (es)
HR (1) HRP20030858A2 (es)
HU (1) HUP0401391A3 (es)
IL (1) IL158390A0 (es)
IS (1) IS6985A (es)
MA (1) MA27017A1 (es)
MX (1) MXPA03009391A (es)
NO (1) NO20034709L (es)
NZ (1) NZ528886A (es)
OA (1) OA12596A (es)
PA (1) PA8544401A1 (es)
PE (1) PE20021137A1 (es)
PL (1) PL366453A1 (es)
PT (1) PT1383482E (es)
PY (1) PY0206703A (es)
SK (1) SK286536B6 (es)
TN (1) TNSN03106A1 (es)
TW (1) TWI264311B (es)
UA (1) UA75135C2 (es)
UY (1) UY27277A1 (es)
WO (1) WO2002087546A2 (es)
YU (1) YU81503A (es)
ZA (1) ZA200307819B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2278861C2 (ru) 2002-03-28 2006-06-27 Пфайзер Продактс Инк. Очищенный лазофоксифен и способ очистки рацемического лазофоксифена рекристаллизацией
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
US7444197B2 (en) 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
WO2008143607A1 (en) * 2006-05-17 2008-11-27 Wm. Wrigley Jr. Company Method of preparing a food product
US8951562B2 (en) 2006-11-10 2015-02-10 Atacama Labs Oy Method and apparatus or dry granulation
FI20080351A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi
FI20070521A7 (fi) 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
CA2671727C (en) * 2006-12-20 2016-02-16 Genpharm Ulc A composition containing a bisphosphonic acid in combination with vitamin d
US20080181972A1 (en) * 2007-01-29 2008-07-31 Valentina Amico Compositions and Methods for Maintaining, Strengthening, Improving, or Promoting Eye Health
BRPI0807581A2 (pt) 2007-02-23 2014-07-01 Gilead Science, Inc. Moduladores de propriedades farmacocinéticas de produtos terapêuticos
SI2296633T1 (sl) 2008-05-02 2015-11-30 Gilead Sciences, Inc. Uporaba trdnih nosilnih delcev za izboljšanje predelovalnih sposobnosti farmacevtskega sredstva
WO2009135946A1 (en) * 2008-05-09 2009-11-12 Atacama Labs Oy Method and apparatus for dry granulation
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
HRP20180709T1 (hr) 2008-06-06 2018-06-15 Boehringer Ingelheim International Gmbh Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona
CA2747396C (en) * 2009-01-29 2015-12-08 Serge Cuypers Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
DK2391349T3 (da) * 2009-01-29 2014-11-03 Ucb Pharma Sa Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
US20140350945A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America System and Method for Validation of Pharmaceutical Composition Formulations
CN103830196A (zh) * 2014-03-14 2014-06-04 王志刚 一种酒石酸拉索昔芬分散片及其制备方法
CN106176649B (zh) * 2016-08-31 2020-04-17 北京斯利安药业有限公司 叶酸vb12片及其制备方法
MX2019009777A (es) * 2017-02-17 2019-10-14 Massachusetts Inst Technology Sistemas y metodos para la fabricacion de tabletas, que incluyen tabletas farmaceuticas.
CZ309820B6 (cs) * 2021-04-23 2023-11-08 Pro.Med.Cs Praha A.S. Způsob přípravy pevné lékové formy obsahující kompozici s nízkým obsahem účinné látky
CN117530926A (zh) 2022-08-02 2024-02-09 江苏众红生物工程创药研究院有限公司 一种舌下片及其在脱敏治疗药物中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725555A (en) * 1967-08-01 1973-04-03 Ciba Geigy Corp Bactericidal compositions and method of killing bacteria using bis-(phenoxyphenyl) carbonates
US3725556A (en) * 1970-11-12 1973-04-03 D Hanssen Method of manufacturing rapidly disintegrating pharmaceutical tablets
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
GB1570993A (en) * 1976-05-21 1980-07-09 Fisons Ltd Pharmaceutical tablet formulation
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US5004613A (en) * 1987-07-27 1991-04-02 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US5107331A (en) * 1989-03-07 1992-04-21 The Color Group Method and apparatus for producing half-tone separations at the same screen angle
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US5976570A (en) * 1993-12-21 1999-11-02 Applied Analytical Industries, Inc. Method for preparing low dose pharmaceutical products
US5928668A (en) * 1993-12-21 1999-07-27 Applied Analytical Industries, Inc. Method for dry blend compression of medicaments
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
US5726168A (en) * 1995-10-12 1998-03-10 Eli Lilly And Company Lipophilic benzothiophenes
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
US5733578A (en) * 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
CA2218756A1 (en) * 1996-10-25 1998-04-25 Kristin Sue Marron Substituted benzo¢b!thiophene compounds having activity as selective estrogen receptor modulators
US6080427A (en) * 1997-04-17 2000-06-27 Bristol-Myers Squibb Company Cefadroxil monohydrate tablet formulation
EP0889056B1 (en) * 1997-07-01 2006-04-12 Pfizer Products Inc. Process for making a cyclodextrin
US6300367B1 (en) * 1999-04-20 2001-10-09 Protein Technologies International, Inc. Composition for and method of preventing or treating breast cancer
US6555551B1 (en) * 1999-08-31 2003-04-29 Mutual Pharmaceutical Co., Inc. Stable formulations of ACE inhibitors, and methods for preparation thereof
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos

Also Published As

Publication number Publication date
NO20034709D0 (no) 2003-10-21
HUP0401391A2 (hu) 2004-12-28
IS6985A (is) 2003-10-09
EA200301040A1 (ru) 2004-04-29
ATE367152T1 (de) 2007-08-15
EP1383482A2 (en) 2004-01-28
TWI264311B (en) 2006-10-21
US7037530B2 (en) 2006-05-02
UA75135C2 (en) 2006-03-15
BG108297A (bg) 2005-07-29
HRP20030858A2 (en) 2005-08-31
CZ20032959A3 (cs) 2004-01-14
AP2003002900A0 (en) 2003-12-31
MXPA03009391A (es) 2004-01-29
IL158390A0 (en) 2004-05-12
WO2002087546A3 (en) 2003-02-13
CA2445519C (en) 2009-01-20
US7176221B2 (en) 2007-02-13
EA005949B1 (ru) 2005-08-25
PE20021137A1 (es) 2002-12-14
EE200300537A (et) 2004-04-15
PT1383482E (pt) 2007-09-20
US20060093667A1 (en) 2006-05-04
KR100568380B1 (ko) 2006-04-05
GEP20053654B (en) 2005-11-10
AU2002236166B2 (en) 2006-12-07
PL366453A1 (pl) 2005-02-07
YU81503A (sh) 2006-08-17
NZ528886A (en) 2005-04-29
GT200200078A (es) 2003-01-31
SK13552003A3 (sk) 2004-09-08
AR033288A1 (es) 2003-12-10
SK286536B6 (sk) 2008-12-05
DE60221238D1 (de) 2007-08-30
US20030004182A1 (en) 2003-01-02
EP1383482B1 (en) 2007-07-18
CA2445519A1 (en) 2002-11-07
JP2004531537A (ja) 2004-10-14
WO2002087546A2 (en) 2002-11-07
PY0206703A (es) 2004-07-01
OA12596A (en) 2006-06-08
DOP2002000389A (es) 2002-11-30
KR20040015226A (ko) 2004-02-18
CN1240375C (zh) 2006-02-08
HK1065705A1 (en) 2005-03-04
MA27017A1 (fr) 2004-12-20
ZA200307819B (en) 2004-10-07
PA8544401A1 (es) 2003-07-28
BR0209283A (pt) 2004-07-13
NO20034709L (no) 2003-10-31
ES2286226T3 (es) 2007-12-01
DE60221238T2 (de) 2007-10-31
CN1531423A (zh) 2004-09-22
HUP0401391A3 (en) 2009-06-29
TNSN03106A1 (fr) 2005-12-23
DK1383482T3 (da) 2007-10-29
UY27277A1 (es) 2002-11-29

Similar Documents

Publication Publication Date Title
ECSP034826A (es) Método para fabricar una composición farmacéutica de dosis baja
UY27886A1 (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco.
SE0100568D0 (sv) Compounds
BR9916224A (pt) Forma de dosagem farmacêutica oral, processos para a manufatura de uma forma de dosagem fixa, para o tratamento e a profilaxia de distúrbios gastrintestinais e para evitar efeitos colaterias gastrintestinais, uso de uma forma de dosagem, combinação, e, embalagem tipo ampola
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
GT199900203A (es) Composiciones de celecoxib.
CO5590918A2 (es) Formulaciones
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
DK1746980T3 (da) Farmaceutisk doseringsform omfattende pellets såvel som deres fremstillingsfremgangsmåde
PE20250018A1 (es) Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-73-fluoro-35- metoxi-32 ,5-dioxo-14-(trifluorometil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola- 2(1,2),7(1)-dibencenaheptafano-74-carboxamida
DK1383540T3 (da) Fremgangsmdåer og farmaceutiske sammensætninger til sårheling
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
ECSP066553A (es) Formas de administración masticables, no comprimidas dosificadas individualmente.
DE60215313D1 (de) Indolderivate und deren verwendung als gnrh antagonisten
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
SE0102440D0 (sv) New compound
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax
HN2001000038A (es) Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina
AR036009A1 (es) Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica
CL2004000767A1 (es) Unidad de dosificacion oral que comprende un agente antagonista de bombas de protones y excipientes de caracter basico; procedimiento para su preparacion, utiles para tratar enfermedades causadas por una secrecion aumentada de acidos gastricos.
SE0101692D0 (sv) Compounds
CR7117A (es) Metodo para fabricar una composicion farmaceutica de dosis baja que tiene una distribucion y potencia del farmaco uniformes
HN2003000048A (es) Comprimido de nelfinavir de dosis incrementada y metodo para fabricarlo
DOP2003000655A (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
AR034701A1 (es) Nuevas composiciones farmaceuticas con accion antidiabetica y proceso para su preparacion